Tasly Biopharmaceuticals Co., Ltd.

Jiangsu Huaiyu Pharmaceutical Co., Ltd.

Xiaodan Cao

Xiaohui Ma

Jian Li

Yan Chen

Lile Liu

Qing Duan

Yibo Wang

Shaoping Hu

Wei Shao

Chen Chen

Lina Wang

Yan Liu

Yanyan Li

Yingying Hu

Xiaohui Shao

Yuandong Wang

Genbei Wang

Jing Li

Lihua Zhang

Mingming Pan

Guoyong Jia

Wenlei Li

Ruijing Huang

Pengyin Wang

Zihan Jin

Ying Gu

Siran Zhu

Yuanyuan Wang

Xiaoxuan Lan

Jun Han

Ping Tai

Baoqing Fan

Yongjie Jin

The invention relates to a method of treatment comprising administering a long-acting mutant human fibroblast growth factor to a subject in need thereof. The said long-acting mutant human fibroblast growth factor is mPEG-CH—NH-mFGF21, wherein mFGF21 consists of SEQ ID NO: 1, and the said new use consists of a method of treating non-alcoholic steatohepatitis.

Method of treating nash using a long-acting mutant human fibroblast growth factor

Provided are a murine or fully human monoclonal antibody targeting SEMA4D and a preparation method therefor, wherein the antibody binds to the SEMA4D antigen and has activities such as combating tumors.

SEMA4D antibody, preparation method therefor and use thereof

The present invention belongs to the technical field of biological pharmacy, and particularly relates to a long-acting HM-3 fusion protein molecule and an application thereof. In the present invention, on the basis of the sequence of HM-3 molecule, an active polypeptide HM-3 and derivatives thereof are linked to a human Fc (IgG) fragment or a fragment of an Fc (IgG) mutant directly or by a linker peptide (Linker), thus forming a novel molecular entity. The general formula of the molecular entity is (HM-3)-Linker-Fc(IgG), Fc(IgG)-Linker-(HM-3), or (HM-3)-Linker-Fc(IgG)-Linker-(HM-3). The fusion protein effectively prolongs the half-life of HM-3, is low in cost and overcomes the major problem of druggability of small peptides. Therefore, the fusion protein of the present invention may serve as a potential drug for the treatment of autoimmune diseases, neovascular diseases, osteoarthritis and the like.

HM-3 fusion protein and application thereof

Growing community of inventors

Shanghai, China

Xiaodan Cao